Home/Pipeline/Sedaconda (isoflurane) via ACD

Sedaconda (isoflurane) via ACD

Sedation of mechanically ventilated ICU patients

ApprovedCommercialN/A

Key Facts

Indication
Sedation of mechanically ventilated ICU patients
Phase
Approved
Status
Commercial
Company

About Sedana Medical

Sedana Medical's mission is to make inhaled sedation a standard therapy in intensive care, representing a significant shift from decades of IV sedation dominance. The company has achieved commercial traction in Europe with its integrated device-pharma platform, reporting 179 MSEK in 2024 sales, and is actively pursuing U.S. market entry through an Early Access Program. Its strategy focuses on direct sales in key European markets, expanding global distribution, and generating clinical evidence to drive adoption and achieve profitability in its ex-U.S. operations.

View full company profile

Therapeutic Areas